Home LiteratureArticle Details
PMID: 6786148 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Initial clinical trial of Mycobacterium tuberculosis antigen 5 in tuberculin-positive human subjects.

The American review of respiratory disease ·Vol. 123 ·No. 5 ·1981-05-00 ·Pages 517-20

Daniel TM, Van der Kuyp F, Anderson PA

Abstract

A single lot of Mycobacterium tuberculosis antigen 5 was used in graded doses to skin test 92 persons in a geographic area where nonspecific tuberculin reactivity is uncommon. In 47 tuberculin-positive subjects, antigen 5 was found to have a potency of 2.7 tuberculin units/micrograms. An intradermal dose of 0.50 microgram was found to give typical delayed skin test reactions in all of 15 tuberculin-positive subjects, with a mean reaction size of 15.17 mm. Some preparations of antigen 5 were found to be unstable during lyophilization and storage; solutions of antigen 5 in diluent containing Tween 80 were stable. Mycobacterium tuberculosis antigen 5 is a potent tuberculin skin test antigen deserving of further clinical evaluation.

MeSH Terms
Antigens, Bacterial/immunology Clinical Trials as Topic/methods Humans Hypersensitivity, Delayed/immunology Injections, Intradermal Mycobacterium tuberculosis/immunology Tuberculin Test/standards
Chemicals
Antigens, Bacterial
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Daniel T M
Van der Kuyp F
Anderson P A
Article Info
Journal
The American review of respiratory disease
Abbr.
Am Rev Respir Dis
ISSN
0003-0805
Published
1981-05-00
Pages
517-20
Language
English
Region
United States
NLM ID
0370523
Subset
IM
Grants
NIAID NIH HHS · 5-R22-AI-15102 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com